[1] 沈璐, 刘巍, 范燕, 等. 论我国药品不良反应监测技术工作的发展阶段[J]. 中国药物警戒, 2012, 9(3):146-148. [2] 国务院. 国务院关于印发“十三五”国家食品安全规划和“十三五”国家药品安全规划的通知[EB/OL].(2017-02-21)[2018-02-08].http://www.gov.cn/zhengce/content/2017-02/21/content_ 5169755.htm. [3] 王丹. 药品不良反应主动监测及其发展趋势[J]. 中国药物警戒, 2015, 12(10): 600-602. [4] 王丹,沈璐. 药品不良反应主动监测的方法与我国的应用[J]. 中国药物评价,2012, 29(1):85-87. [5] 侯永芳, 沈璐, 刘巍, 等. 美国医疗产品安全主动监测系统概述及启示[J]. 中国药物警戒, 2017, 14(1):32-35. [6] Zhang X, Faries D E, Li H, et al.Addressing unmeasured confounding in comparative observational research[J]. Pharmacoepid-emiol Drug Saf, 2018, 27(4): 373-382. [7] Chen Y, Briesacher B A.Use of instrumental variable in prescription drug research with observational data: A systematic review[J]. J Clin Epidemiol, 2011, 64(6): 687-700. [8] Uddin M J, Groenwold R H, Ali M S, et al.Methods to control for unmeasured confounding in pharmacoepidemiology: An overview[J]. Int J Clin Pharm, 2016, 38(3): 714-723. [9] Baiocchi M, Cheng J, Small D S.Instrumental variable methods for causal inference[J]. Stat Med, 2014, 33(13): 2297-2340. [10] Davies N M, Smith G D, Windmeijer F, et al.Issues in the reporting and conduct of instrumental variable studies: A systematic review[J]. Epidemiology, 2013, 24(3): 363-369. [11] Cai B, Small D S, Have T R.Two-stage instrumental variable methods for estimating the causal odds ratio: Analysis of bias[J]. Stat Med, 2011, 30(15): 1809-1824. [12] Swanson S A.Instrumental variable analyses in pharmacoepidemiology: What target trials do we emulate?[J]. Curr Epidemiol Rep, 2017, 4(4): 281-287. [13] 杨羽, 詹思延. 上市后大数据药品安全主动监测模式研究的必要性和可行性[J]. 药物流行病学杂志, 2016, 25(7): 401-404. |